348642-86-4Relevant articles and documents
Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth
Qiao, Lixin,Zhao, Lian-Yun,Rong, Suo-Bao,Wu, Xiong-Wu,Wang, Shaomeng,Fujii, Teruhiko,Kazanietz, Marcelo G,Rauser, Laura,Savage, Jason,Roth, Bryan L,Flippen-Anderson, Judith,Kozikowski, Alan P
, p. 955 - 959 (2007/10/03)
In view of its role in tumor promotion and signal transduction, protein kinase C (PKC) has proven to be an exciting target for cancer therapy. With the aid of molecular modeling, we rationally designed and stereoselectively synthesized a new class of rigidified pyrrolidone-based PKC activators. Pyrrolidone 15 was found to exhibit reasonable affinity for PKCδ, with lower affinity for the other isozymes tested. Pyrrolidone 2 causes the dose-dependent induction of apoptosis in LNCaP prostate cancer cells. This apoptotic effect could be markedly potentiated by the use of LNCaP cells overexpressing the PKCα or δ isozymes.